Probiodrug AG (PBD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Probiodrug AG (PBD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013929
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:55
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Probiodrug AG (Probiodrug) is a biopharmaceutical company that conducts research and development of therapies for Alzheimer’s disease. The company provides three pipeline drug candidates such as PQ912, PBD-C06 and PQ1565. Its PQ912 drug candidate is a small molecule glutaminyl cyclase (QC) inhibitor in Phase II clinical trials that inhibits QC-enzyme for animal models. Probiodrug’s PBD-C06 is a monoclonal antibody under evaluation, which clear toxic pyroglutamate-Abeta (pGlu-Abeta) in the brain. The company’s PQ1565 is a second QC inhibitor in preclinical stage and demonstrated attractive drug-like properties. It developes a therapeutic approach, dipeptidyl peptidase 4 (DP4) inhibitors for the treatment of diabetes. Probiodrug is headquartered in Halle, Germany.

Probiodrug AG (PBD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Probiodrug AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Probiodrug AG, Medical Devices Deals, 2011 to YTD 2017 10
Probiodrug AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Probiodrug AG, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Probiodrug Secures US$19.5 Million In Series C Financing 12
Partnerships 14
Probiodrug to Enter into Agreement with Julius Clinical 14
Probiodrug Enters into Research Agreement with Paul-Flechsig-Institute 15
Probiodrug Enters Into Co-Development Agreement With VU University Medical Center 16
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 17
Licensing Agreements 18
Probiodrug Enters into Licensing Agreement with Crossbeta Biosciences 18
QPS Austria Enters into Licensing Agreement with Probiodrug 19
Equity Offering 20
Probiodrug Prices Private Placement of Shares for USD17.8 Million 20
Probiodrug Raises USD14.7 Million in Private Placement of Shares 22
Probiodrug Completes IPO for USD29.6 Million 23
Asset Transactions 25
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 25
Probiodrug AG – Key Competitors 27
Probiodrug AG – Key Employees 28
Probiodrug AG – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Aug 31, 2017: Probiodrug reports financial results for H1 2017 and corporate update 30
May 12, 2017: Probiodrug reports First Quarter 2017 Business Update 34
Mar 30, 2017: Probiodrug reports full year 2016 financial results 36
Nov 10, 2016: Probiodrug Reports Third Quarter 2016 Business Update 40
Aug 30, 2016: Probiodrug reports financial results for H1 2016 43
Mar 15, 2016: Probiodrug reports full year 2015 financial results 46
Corporate Communications 49
Aug 12, 2016: Probiodrug Announces Changes to the Supervisory Board and Executive Management 49
Mar 23, 2016: Probiodrug Appoints Mark Booth as Chief Business Officer 50
Product News 51
03/09/2016: Probiodrug PGLU-ABETA Approaches Being Presented At 14Th Aat Symposium On Advances In Alzheimer Therapy 51
Clinical Trials 52
Nov 16, 2016: Amyloid-beta (Abeta) aggregate-clearing by the murine anti-pyroglutamate-3 Abeta IgG2a monoclonal antibody PBD-C06 with and without a complement mutation in an Alzheimer’s mouse model 52
Sep 07, 2016: Promising new findings for Probiodrug’s Glutaminyl Cyclase – inhibitor in an inflammation animal model 53
Apr 04, 2016: Probiodrug announces results of chronic toxicology studies with PQ912, its ‘first in class’ Glutaminyl Cyclase inhibitor for the treatment of Alzheimer’s disease 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55

List of Tables
Probiodrug AG, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Probiodrug AG, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Probiodrug AG, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Probiodrug AG, Deals By Therapy Area, 2011 to YTD 2017 9
Probiodrug AG, Medical Devices Deals, 2011 to YTD 2017 10
Probiodrug AG, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Probiodrug Secures US$19.5 Million In Series C Financing 12
Probiodrug to Enter into Agreement with Julius Clinical 14
Probiodrug Enters into Research Agreement with Paul-Flechsig-Institute 15
Probiodrug Enters Into Co-Development Agreement With VU University Medical Center 16
Evotec Enters Into Co-Development Agreement With Probiodrug For Glutaminyl Cyclase 17
Probiodrug Enters into Licensing Agreement with Crossbeta Biosciences 18
QPS Austria Enters into Licensing Agreement with Probiodrug 19
Probiodrug Prices Private Placement of Shares for USD17.8 Million 20
Probiodrug Raises USD14.7 Million in Private Placement of Shares 22
Probiodrug Completes IPO for USD29.6 Million 23
AstraZeneca Acquires CDK9 Inhibitor Program From Probiodrug 25
Probiodrug AG, Key Competitors 27
Probiodrug AG, Key Employees 28
Probiodrug AG, Subsidiaries 29

★海外企業調査レポート[Probiodrug AG (PBD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Grupo T-Solar Global SA:電力:M&Aディール及び事業提携情報
    Summary Grupo T-Solar Global SA (T-SOLAR), a subsidiary of Isolux Infrastructure Netherlands BV, is a renewable energy company that generates electricity using photovoltaic technology. The company owns and operates photovoltaic power plants. It offers development, financing and construction, managem …
  • Schneider Electric SE (SU)-石油・ガス分野:企業M&A・提携分析
    Summary Schneider Electric SE (Schneider Electric), formerly Schneider Electric SA, is an energy management and automation company that develops related technologies and solutions for electricity distribution. Its product line comprises automation and control products, building management and securi …
  • HealthEquity Inc (HQY):企業の財務・戦略的SWOT分析
    Summary HealthEquity Inc (HealthEquity) is a healthcare service provider that offers health savings management services. The company provides integrated health accounts such as health savings account, health reimbursement arrangements, flexible spending accounts for health plans, insurance companies …
  • Steelcase Inc.
    Steelcase Inc. - Strategy, SWOT and Corporate Finance Report Summary Steelcase Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Hunter Engineering Co:企業の戦略的SWOT分析
    Hunter Engineering Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • e-Therapeutics Plc (ETX):企業の財務・戦略的SWOT分析
    e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • BKW AG (BKW):電力:M&Aディール及び事業提携情報
    Summary BKW AG (BKW) is an energy and infrastructure company, which plans, builds and operates infrastructure to produce and supply energy. It generates electricity from varied fuel sources such as hydro, nuclear, fossil, and renewable sources primarily, wind and small hydro, besides solar and bioma …
  • PRA Health Sciences Inc (PRAH):企業の財務・戦略的SWOT分析
    Summary PRA Health Sciences Inc (PRA) is a contract research organization (CRO) which provides clinical development services. The company offers services which include phase I-IV study management, bioanalytical services, biometrics, clinical pharmacology, strategic solutions, post-marketing research …
  • Oncolytics Biotech Inc (ONC)-医療機器分野:企業M&A・提携分析
    Summary Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product, Reolysin, a formulation of the human reovirus, is at Phase II clinical trials indi …
  • eResearchTechnology Inc:企業の戦略的SWOT分析
    eResearchTechnology Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • NGEx Resources Inc:企業のM&A・事業提携・投資動向
    NGEx Resources Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's NGEx Resources Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • UbiQ Bio BV:製薬・医療:M&Aディール及び事業提携情報
    Summary UbiQ Bio BV (UbiQ) is a biotechnology company that develops and commercializes ubiquitinated peptides and assays that enables drug discovery in Ubiquitin field. The company provides products such as ubiquitin-proteasome system, high throughput screening assay reagents and ubiquitinated polyp …
  • PT Telekomunikasi Indonesia Tbk (TLKM):企業の財務・戦略的SWOT分析
    PT Telekomunikasi Indonesia Tbk (TLKM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Kuros Biosciences AG (KURN):企業の財務・戦略的SWOT分析
    Kuros Biosciences AG (KURN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Latvenergo AS-エネルギー分野:企業M&A・提携分析
    Summary Latvenergo AS (Latvenergo) is a state-owned power supply utility company that generates and supplies electricity and thermal energy, distributes electricity, leases transmission system assets. It generates electricity through various renewable energy sources such as hydropower, biomass, wind …
  • Verizon Communications Inc (VZ):企業の財務・戦略的SWOT分析
    Verizon Communications Inc (VZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Flatiron Health Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Flatiron Health Inc (Flatiron Health) a subsidiary of F. Hoffmann-La Roche Ltd, is a healthcare technology company which develops a learning healthcare system in oncology. The company offers a web-based business and clinical intelligence data platform that integrates and structures disparate …
  • Vericel Corp (VCEL):企業の財務・戦略的SWOT分析
    Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Edison SpA:発電所・企業SWOT分析
    Edison SpA - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • Humabs BioMed SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Humabs BioMed SA (Humabs), a subsidiary of Vir Biotechnology Inc, is an antibody therapeutics biotechnology company that discovers and develops human monoclonal antibodies. The company’s pipeline programs include Flu A virus, ebola virus, HBV, rabies virus, JCV, dengue, and others. It develo …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆